The recent Phase II VinCap trial (NCT02057913) shows promising results for vinflunine as a chemotherapy for locally-advanced and metastatic carcinoma of the penis. At the Genitourinary Cancers Symposium, in San Francisco, CA, Lisa Pickering, MRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, provides a detailed and concise review of vinflunine. Dr Pickering discusses the results of the VinCap trial, depicting the advantages of vinflunine in efficacy, tolerability, and meeting its primary endpoint and clinical benefit rate compared to other chemotherapies.
Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer
